OTC · MDGEF
Medigene AG
$2.59$0.00 (0.0%)
Medigene AG’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · PBIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pressure BioSciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pressure BioSciences, Inc.’s next earnings report is currently expected on Nov 24, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pressure BioSciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company’s products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products. The company also provides pain relief, skincare solutions, personal wellness, athletic recovery, and specialized pet care products. It serves researchers at academic laboratories, government agencies, biotechnology and pharmaceutical companies, other life science institutions, and food/beverages laboratories. The company has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. Pressure BioSciences, Inc. was incorporated in 1978 and is headquartered in Canton, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:48 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Aug 21, 2023 | -$0.57-147.9% vs estimate | $511.80K+0.77% vs estimate |
|---|
| Q1 2023 | May 16, 2023 | -$0.46-132.17% vs estimate | $740.60K+747.57% vs estimate |
|---|
| Q1 2023 | Apr 12, 2023 | -$0.37-118.97% vs estimate | $607.17K-90.5% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.59$0.00 (0.0%)
Medigene AG’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.02$0.00 (0.0%)
United American Healthcare Corporation’s quoted price sits in the lower half of its reported 52-week range, 30.77% below the high.
$0.08+$0.01 (+20.25%)
Panacea Life Sciences Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 40.86% below the high.
$0.00$0.00 (0.0%)
Hemp, Inc’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Neon Bloom, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.56% below the high.
$0.02$0.00 (0.0%)
ModivCare Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.76% below the high.
$0.00$0.00 (0.0%)
StageZero Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 91.45% below the high.
$0.00$0.00 (0.0%)
Medical Supply International USA, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
